CMI conclusions from clinical studies (adapted and modified with permission from [90]).
Abstract
Among the numerous infectious diseases, malaria still remains the main cause of morbidity and mortality across the world. Every year more than 200 million cases are registered and death toll is of around 4,00,000. The emergence of insecticide and drug resistance has surged an alarming situation to find an effective means to tackle it. From various approaches used for reducing the damage created by malaria to the society, developing effective vaccine has gained the attention of scientific community. The large genome size (24 MB), heterogeneity of the genes, complex life cycle in two different hosts, and expression of wide range of these genes are claimed to hinder the malaria vaccine development. It requires good understanding of the host-pathogen interaction and its correlation with the sterile protection. Recently, subunit vaccine have shown certain promising responses; however, the currently in use of RTS,S vaccine has failed to generate the long-term sterile protection as well as effector memory CD8+T cells. However, the success of sterile protection through vaccination has been proven long back by experimental approaches, where it could be achieved using irradiated sporozoites (RAS) in rodents and humans. Similarly, GAP (genetically attenuated parasite) and CPS (chloroquine chemoprophylaxis with Plasmodium sporozoites) have been shown to induce sterile immunity. Despite all the developments, generation of species and stage specific-CD8+ T cell responses has been modest. In order to generate long-lasting immune response, particularly, liver-stage specific-CD8+ T cells, it is indeed required to study the CD8+ T cell epitope repertoire and its implications on the host immune system. In this chapter we will discuss the current status of T cell-based vaccines and the challenges associated with it.
Keywords
- Malaria
- subunit vaccine
- CD8+ T cells response
- sterile immunity
- memory T cells
1. Introduction: Malaria pathogenesis
Since the origin of
Despite the reduction in the malaria mortality rate (from 25% in 2000 to 10% in 2019), the children under the age of 5 years are the most vulnerable group (due to the lack of adequate acquired immunity) as 67% of total death in 2019 was reported in this group. Likewise, pregnant women are also at the higher risk as it quells the immune system [2, 4]. Athwart the other Apicomplexa parasites having the commodious range of metazoans for the infection,
The
2. Malaria elimination and eradication: Grasping at straws
It was 1897 when Ronald Ross has identified the parasites responsible for the malaria infection and later on the development in the field of science and technology has opened up several areas to work upon and eliminate the malaria infection [15]. The basic understanding of epidemiology and entomology, host-pathogen interaction, surveillance and numerous studies have provided the information about the usage of two main prophylactic methods to curtail down the morbidity and mortality spread by malaria infection: prevention of infection and diseases by controlling the mosquitoes and usage of antimalarial therapy, respectively. As per the recommendation by WHO, insecticides-treated nets (ITNs) have been used to prevent the insect from reaching out the humans. Nonetheless, the results were discouraging as less than 2% children were protected in African region through the usage of ITNs [16]. Further, to surpass the limitation of ITNs, spraying of various insecticides (such as DDT, permethrin, deltamethrin, pyrethriods) have come into the practice, although it has only cover the tip of the iceberg [17]. To strengthen the above approaches WHO has launched the global malaria eradication program in early 1955 [18] and DDT & chloroquine have been recommended for the ITNs and prevention and treatment of infection, respectively [19]. Despite significant reduction in several developing and underdeveloped countries, the reports of
Likewise, the drug resistance against the frontline antimalarial drug quinine has forced the mankind to use the other drugs and combination. However, the reports of resistance against the artemisinin in Greater Mekong Subregion (GMK) in a short span of its launch [26] and unavailability of other options for artemisinin combination therapy (ACT) have invoked the bleak condition for the treatments [27]. To prevail the condition of drug resistance, scientist have opted for mass drug administration (MDA) approach in which antimalarial drugs have been recommended to the specific group of people without getting into the details of their illness. It has been further known as
Apart from the well-known approaches, usage of antibiotics and their role to fight against the various diseases is widely accepted and therefore, azithromycin, doxycycline and clindamycin have been tested against the malaria. These antibiotics were found to be effective and also reached to the clinical phases; yet the delayed response is the major drawback due to which they cannot be utilized in mild-to-severe and severe conditions of malaria [30]. Besides, a range of antibiotics named quinoloes, tetracycline, trimethoprim, erythromycin and others are in the early stage of development as they are showing promising results which kill the parasites [31], yet it has a long way to go.
Alongside the approaches used to control the malaria infection, human body also consists of a defense mechanism which respond according to the nature of threat (humoral and cell mediated immunity). It is believed that people living in malaria endemic areas naturally develop immunity due to the continuous exposure of malaria infection. However, age, gender, geographical location, time (months to several years) and numerous other factors are considered to play a vital role in long-term protection [32, 33, 34] against malaria. Despite the characteristics of developing protection against the malaria infection naturally, the poorly understood mechanism and the long-term protection are controversial. Therefore, it is of utmost priority to gain the sterile protection against the malaria infection.
2.1 Approach of vaccine development: A ray of hope
Number of experimental approaches have been adopted to understand the
After successful immunization strategy of X-irradiation in non-human host, Clyde
As discussed earlier, it is possible that people living in malaria endemic can develop naturally acquired immunity after prolonged exposure although it could be restricted to blood-stage infection. However, induction of immunity to liver-stage (LS)infection among endemic population has not been thought to be possible because of lower infection load, heterogeneity of liver immunology of individuals and characteristics which differ from blood stage [41]. Also, among the different stages of malaria infection, blocking the transmission of human-to-mosquitoes-to-human and generation of modified mosquitoes may halt the spreading of malaria are in dire straits conditions. Similarly, to target particularly the infected RBCs containing merozoites and preventing them to infect other RBCs in the blood/symptomatic stage has been very difficult. Nonetheless, the longest exposure of infected sporozoites towards the host immune system by invading hepatocytes in the liver stage (5.5 to 7 days in humans and 48 hrs in rodents) and releasing of thousands of merozoites which further continue the blood-stage or symptomatic stage of infection makes the LS most promising stage for the target of vaccine development [14, 42], though LS-vaccine has its own limitation of tedious and challenging task of sporozoites.
Taking into the above considerations, scientific community across the globe is working on multiple targets of different stages to tackle the dire condition. At present, there are mainly three types of vaccines based on the life-cycle: the liver (pre-erythrocytic) stage (LS), asexual blood (symptomatic) stage and the third one is transmission blocking vaccines (TBV).
2.1.1 History of malaria vaccine development
The successful experimental approach of using the attenuated sporozoites (
The advancement in the field of sequencing helped in identifying the region of CSP protein having species-specific immunodominant epitope that consists of tandem repeated sequences of amino acids, Asn-Ala-Asn-Pro-Asn-Ala-Asn-Pro-Asn-Ala-Pro (NANP)3, remain conserved and found to be present in most of the people. The outcome of this work has led the pioneers to develop the approach of
Further, parasite-specific Ags presented by MHC I and II to the CD8+ and CD4+ T cells, respectively on the surface of infected hepatocytes [64, 65, 66, 67, 68] delineate the importance of cell mediated immunity (CMI) to target the LS infection. All the above and other experimental evidences have unveiled the prominent role of CMI in generating sterile protection. As a result, it has changed the scenario in the field of vaccine development and to generate the sterile protection via boosting up CMI through a novel approach of
The technological advancement in the field has helped the scientific community to understand host-pathogen interaction in detail. As a result of it, numerous new and improvised approaches come into practice for the successful vaccine development. To review the status of vaccine candidates and accelerate the development of second generation malaria vaccines, several scientific meetings and forums [72, 73] were organized as well as provided the literature for the same [17, 55, 74, 75]. Therefore, here we have not discussed about all the different types of vaccines.
In early 1980s,
Targeting the
Similarly,
Apart from LS and BS, researchers have also explored the third vaccine type,
2.1.2 RTS,S malaria vaccine: Learning lessons from gained knowledge
RTS,S (a recombinant protein based vaccine) was first developed by SmithKline Beecham Biologicals (now known as GlaxoSmithKline Vaccines) in the early 1980s, and has become the first ever licensed vaccine approved by European regulators to use against the human parasite infection in 2015 [87]. From the early experimental studies, modification has been adapted and the novel RTS,S is combined with AS01 (a liposomal formulation) or AS02 (a emulsion based formulation) adjuvant system which trigger the toll-like receptor (TLR4) mediated cytokines and appropriate co-stimulatory signaling molecules on APCs. Additionally, it also activates both wings of the immune system against the CSP and able to generate sterile protection in
Vaccine schedule (location) | Vaccine type | No. of samples analyzed | CMI conclusion |
---|---|---|---|
0, 1, 6 month Belgium | RTS,S/AS02 | 10 | CSP-specific IFN-γ ELISPOTs were induced in 8/10 subjects. RTS, S-specific IFN-γ production was induced in all subjects. LPR to CSP were induced in all subjects. CSP-specific CD8+ CTL responses were not detected |
0, 1, 2 month Belgium | RTS,S/AS01 RTS,S/AS02 RTS,S | 11 11 12 | CS-specific CD4+ T-cell responses (i.e. cells expressing at least 2 markers among CD40L, IL-2, TNF-α, and IFN-γ) were detected in all vaccine groups with a trend for higher responses in the RTS,S/AS01 and RTS,S/AS02 groups versus the RTS,S group |
0, 2, 6 month USA | RTS,S/Alum RTS,S/AS04 | 10 10 | One of two protected subjects had RTS,S and CSP-specific LPR and cytotoxic T-cell activity |
0, 1, 7 month USA | RTS,S/AS02 RTS,S/AS03 RTS,S/AS04 RTS,S/AS02 RTS,S/AS03 RTS,S/AS04 RTS,S/AS02 RTS,S/AS03 RTS,S/AS04 | 07 07 08 01 05 01 07 07 06 | Highest rate of protection with RTS,S/AS02 although CMI results inconclusive Inconclusive due to small sample size IFN-γ ELISPOTs associated with level of protection, ∼2 weeks after Dose 3 and on DOC. Protection most frequent for RTS,S/AS02 recipients |
0, 1, 2 month USA | RTS,S/AS01 RTS,S/AS02 RTS,S/AS01 RTS,S/AS02 | 36 44 36 44 | Association between CSP-specific CD4+ T cells and protection, 2 weeks after Dose 3 and on DOC. Association between short duration IFN-γ ELISPOTs and protection. Higher frequency of CSP-specific CD4+ T cells with RTS,S/AS01 vs. RTS,S/AS02A Association between CSP-specific IL-2+ CD4+ T-cell central-memory and effector-memory populations and protection |
0, 1, 2 month USA | RTS,S/AS01 (group RRR) Ad35.CS.01 (dose-1) & RTS,S/AS01 (dose-2 & 3; group ARR) | 25 21 | No evidence of independent association between CSP-specific CD4+ T cells or IFN-γ ELISPOTs and protection. No difference in protection between groups. CMI responses significantly greater in AAR group than in RRR group |
0, 1, 6 month Gambia | RTS,S/AS02 | 20 | CSP-specific LPR, short duration IFN-g ELISPOT levels were increased by vaccination. All 20 vaccine recipients responded to at least one of the CMI tests after Dose 3 whereas only 15/20 responded before vaccination. No CMI data on protection |
0, 1, 5 month Gambia | RTS,S/AS02 Rabies RTS,S/AS02 Rabies | 16 16 ≤131 ≤119 | Higher LPR in RTS,S/AS02 recipients than in rabies-vaccine recipients two weeks after Dose 3 An association between long duration IFN-γ-ELISPOT response and protection was seen across the total population of vaccine recipients and controls, and was not caused or confounded by vaccination with RTS,S/AS02. A significantly higher level of IFN- γ-ELISPOTs was also observed in RTS,S/AS02 vaccine recipients compared with rabies-vaccine recipients at 11 weeks after Dose 3. |
0, 1, 2 month Mozambique | RTS,S/AS02 HBsAg | ≤63 ≤69 | Significant induction of IL-2 secretion in CSP re-stimulation cultures in 24% of RTS,S vaccine recipients. IL-2 secretion was detected in CSP-re-stimulation cultures from 32% of individuals without a malaria episode whereas IL-2 secretion was detected in only 6% of individuals with malaria episodes (p = 0.053) |
0, 1, 2 month Gabon | RTS,S/AS01 RTS,S/AS02 | ≤31 ≤32 | The frequencies of IL-2+ CD4+T cells were higher than pre-immune levels in both RTS,S vaccine groups. CD40L+ CD4+ T cells were not detected. Responder rates ranged from 13–29%. No CMI data on protection |
0, 1 month; 0, 1, 2 month; and 0, 1, 7 month Ghana | RTS,S/AS01 RTS,S/AS02 Rabies (0, 1, 2 month only) | ≤77; ≤37; ≤73 ≤80; ≤38; ≤73 ≤45 | Higher no. of IL-2+ CD4+T cells with compare to other marker positive CD4+ T cells (and responder rate of 76% 1 month after dose 3 with 0, 1, 7 month schedule). CD40L+ CD4+ T cells were detected in 0, 1, 7 schedule. Highest T-cell responses were induced by a 0, 1, 7-month immunization schedule (and responder rate of 73% 1 month after dose 3 with 0, 1, 7 month schedule). RTS,S/AS01E induced higher CD4+ T-cell responses than RTS,S/AS02 for the 0, 1, 7-month schedule. No CMI data on protection |
0, 1, 2 month Kenya/Tanzania | RTS,S/AS01 Rabies RTS,S/AS01 Rabies | ≤182 ≤ 197 ≤80 ≤ 98 | The frequency of RTS,S-induced CSP-specific (IFNγ−IL-2−)TNF-α+ CD4+ T cells was associated with protection, and CSP-specific TNF-α+ CD4+ T-cell responses and anti-CSP antibody responses were synergistically associated with protection Evidence that IL-2+-secreting CSP-stimulated memory CD4+T cells can activate NK cells to secrete IFN-γ. IFN-γ ELISPOTs may include IFN-γ-secreting activated NK cells. No CMI data on protection. |
Later on, Strategic Advisory Group of Experts on Immunization (SAGE) of WHOs and Malaria Policy Advisory Committee (MPAC) have jointly recommended a pilot study for the vaccination in Africa; it has began in Malawi, Ghana and in Kenya between the April and October, 2019 [96]. Despite the approval of RTS,S vaccination, the issue of safety in children is well-documented and therefore, combination of different novel adjuvants with change in the length of CSP-specific peptides and structural information of CSP-specific Abs may further improve the efficacy of RTS,S vaccine [97]. Subsequently, a next generation vaccine was developed (R21) and accounted for the improvised version of RTS,S as it incorporates the longer portion of
The development and efficacy of RTS,S vaccine in clinical trials and field study have confirmed the role of T-cell based sterile protection. Recent advancement in the field of genetics and structural biology has driven the area and again the older approach of
2.2 Whole sporozoite vaccines
It has been well-documented that malaria life cycle begins with the invasion of hepatocytes (in liver) by sporozoites; if restrained its development to the LS, the immune responses to
2.2.1 Chemo- prophylaxis and sporozoites (CPS)
Under this approach, live sporozoites are delivered alongside the available anti-malarial drugs with the aim of targeting BS infection, generation of elevated humoral response and followed by understanding the LS infection. In this direction, the first study was conducted in mice under the cover of chloroquine (CQ) and found to be protective with more number of CD8+IFN-γ+ T cells [100]. In the following years, the first human trial was conducted under the cover of CQ in CHMI and found to be 100% effective after homologous challenge, and more interesting, some of the volunteers remain immune for around 2 years [101]. The study of elevated immune response depicted the major role of memory T cells producing IL-2, TNF-α and IFN-γ. It has been noticed that higher dosage in homologous CHMI enhances the protection level. However, during the heterologous challenge study, protection was found to be remained limited, raising the question for its efficacy against the diversity of
2.2.2 Radiation attenuated sporozoites (RAS)
As mentioned earlier, mice immunized with x-ray irradiated sporozoites (
2.2.3 Genetically attenuated sporozoites (GAS)
To overcome the existing hurdles of RAS, novel approach of genetic manipulation was explored in
After the success of initial GAS study, several other genes (
Despite the yin and yang of GAS in clinical studies, it has been considered as more accurate and doable approach with compare to RAS. Additionally, with the novel technology of CRISPR-Cas9, various attenuated sporozoites can be generated which might be more immunogenic in nature and aid in generating stronger immune response.
All the different approaches of vaccine development strongly suggest the correlation of T-cells and protection against malaria infection. And, therefore it may be a decisive player in enhancing the efficacy of vaccine. By keeping in mind the importance of T-cell, in the next section we have discussed the role of T-cell based immunity in all the stage of infection as well importance of it in developing T-cell based vaccines.
3. T-cell based immune response: A key player of vaccine development
From the very beginning, it has been well documented that T-cells play an important role in protection and generation of sterile immune response in malaria infection. Once the sporozoites enter into the host live and invade the hepatocytes, APCs process and present the
3.1 T-cell response: In early stage of sporozoites
During the blood-meal of
3.2 T-cell response: In pre-erythrocytic stage (LS)
In continuation of early stage infection, once the sporozoites reach to the liver, LS infection cycle initiates and through a cascade of mechanisms, numbers of schizonts are formed between the periods of 5–6 days.
3.3 T-cell response: In blood stage (asexual/symptomatic stage)
The release of merozoite from schizonts confirms the beginning of erythrocytic stage, where they invade the naïve RBCs, convert into trophozoites and develop thousands of merozoites which are ready to burst from the infected RBCs (iRBCs) and target the new RBCs. Due to the lack of MHC molecules, iRBCs cannot perform the Ag presentation to T cells. However, it is believed that iRBCs bind to DCs and macrophages through the receptor-ligand (of parasite) interaction and after the maturation, most of the DCs migrate to the spleen where they present the Ag via MHC-molecules to the naïve –T cells [123]. The role of DCs in the generation of BS specific Ab is studied in animal models. Experimental evidences have shown the emerging role of novel T-cell population of γδ+ and αβ+ in the generation of IFN-γ responses that control the BS infection of
3.4 T-cell response: Towards the blood stage sexual parasites
During the blood-stage asexual cycle, certain number of parasites come out from the RBCs cycle and develops into male and female gametocytes. Till date very little literature is available about the T-cell response against the gametocytes. The first study conducted in 1997 where purified
The discovery of novel T-cell populations and their role in generating sterile protection alongside the conventional T-cells at each stage of malaria infection, aid the malaria biologist especially vaccinologists to design highly efficacious vaccine based on T-cells. Therefore, we have discussed about the different T-cells and their role in antigen diversity.
3.5 T-cell and their subtypes: Role in protective immunity against malaria
The induction of
As CD4+ T cells are important in generating strong immune response by activating humoral and CMI response, the role of
Recently, a novel population of
3.6 T-cell response: Effect of Plasmodium Ag(s) diversity
It has been studied that due to the polymorphic nature of Ag(s), effector function of CD8+ T cells and MHC-I peptide presentation become less prominent; as a result, during the secondary infection, it overcomes the immune system and establish LS infection [137]. Thus, with the help of sequencing technology conserved and variable epitopes of CSP and other potential target Ag(s) were found and reported [114]. Similar results were observed during RTS,S clinical trials, in which higher efficacy was observed in those children’s whose parasitic infection matches the T-cell based Th2R and Th3R epitope as compared the mismatched one [138]. It has been found in another gene based vaccine study that CD8+ T cells based response is restricted to HLA-I of AMA1 Ag of 3D7 strain but failed to act against the AMA1 Ag of 7G8 strain that has the difference of only single amino acid [139]. It has been strongly supported by the earlier report of CSP where single amino acid replacement have an impact on T-cell based immune response [140]. Thus, antigenic polymorphic nature and substitution of single/multiple amino acids in the epitopes may result in less interaction between T-cell peptide and MHC molecule causing the failure in generation of protective immunity.
3.7 T cells and vaccine development
The first licensed malaria vaccine RTS,S was designed by incorporating mainly B cell epitopes that induced humoral response. The Ab-mediated response may aid the induction of T-cells and evidence have shown the CD4+ T cells response, yet it is unable to understand that after RTS,S vaccination why immunity is remain short-lived. It may possible that incorporation of appropriate CD8+ T cells based epitope which further enhance the sterile immunity. Additionally, it is also been interesting to study the role of B cells in direct/indirect activation of CD8+ T cells. On the other hand, different approaches under the roof of whole sporozoite vaccine (CPS, RAS and GAS) depicted the prominent role of CD4+ and CD8+ T cells in protective responses against malaria infection in rodents, whereas in humans (under CHMI study) it has been limited to peripheral blood only. Additionally, among different subsets of T-cells which play a crucial role in providing protection and signaling pathway is yet to be fully understood. As mentioned earlier, injection of attenuated sporozoites through RAS approach have shown the antimalarial immunity against LS infection. Therefore, multiple antigenic targets of LS may help in generating strong liver-resident memory T cells. These WSV approaches have their own limitation and to prevail it, another approach of viral vector bearing Ag delivery has been explored and have shown the promising results [141]. After successful pilot study, to elicit the stronger T-cell based response several other options such as usage of nanoparticle based delivery system [142] and adeno-associated virus have been tried.
As T-cell mediated immunity is having prominent role in generating sterile protection, RAS and subunit vaccine approach which can induce stage-specific T-cell immune response and restrain the LS infection should be considered. Recently, all the experimental evidence have demonstrated that instead of using single epitope based Ag, multiple-and-stage-specific epitopes of different Ag(s) can protect and generate stage-specific sterile response, yet it has to be verified in animal settings before going for the clinical trials. Also, poor immunogenicity of stage-specific Ag(s) required screening the whole genome database and available RNA-seq. data which can predict and identify (with matched HLA-typing) B-and-T-cell based epitopes to activate the immune response in a controlled manner. To overcome the current challenges mainly in T-cell based vaccine development below-listed novel approaches may aid in better results. Figure 4 depicted the major pathway of immune response and how they can be triggered by T-cell based vaccine.
Reverse vaccinology
Structural vaccinology
Immunoinformatics
High-throughput identification for immune protection
Understanding the humoral and CMI response
Selection of appropriate platform for vaccine development and delivery
4. Conclusion
Malaria still persists as a major global challenge and to fight against it several options have been explored. Despite the advancement in the field of technology, drug and insecticide resistance followed by recent threat of delayed clearance of parasite against the frontline of antimalarial(s) have created herculean situation. On the other hand, RTS,S is the only licensed vaccine against the malaria infection, which is also unable to reach the expectation in generating sterile protection. Significant role of T-cells (mainly CD4+ and CD8+ T-cells) is found to be a key-player against the malaria infection. To elicit the T-cell based response, novel approaches of vaccine development have been adopted and some of them are currently in pipeline of clinical trials. The older approach of WSV has recently gained the interest because of their potency to induce T-cell responses. The changes in RTS,S vaccine design via incorporating T-cell epitopes later on together with B-cells strongly support that finding of T-cell based multiple-epitope which can accelerate the immune response and aid Ab formation having immunogenicity in nature. By using the recent reverse vaccinology, structural based finding epitopes and predicted immunogen may aid in providing additional support in T-cell induction which are protective in nature.
Acknowledgments
Prof. Sarat K. Dalai would like to thank the Department of Biotechnology (DBT), New Delhi, Govt. of India for funding part of study (BT/PR34451/MED/29/1482/2019, SAN NO. 102/IFD/SAN/1633/2020-2021). Nikunj Tandel thanks the Indian Council of Medical Research (ICMR), New Delhi, Gov. of India for providing fellowship for his research (ICMR-SRF No.: 2020-7623/CMB-BMS).
References
- 1.
Watkins, K. Emerging infectious diseases: A review. Current Emergency and Hospital Medicine Reports 2018 ,6 , 86-93, doi:10.1007/s40138-018-0162-9. - 2.
WHO. World malaria report 2020 : 20 yeras of global progress and challenges ; World Health Organization: 2020. - 3.
Mahmoudi, S.; Keshavarz, H. Malaria vaccine development: the need for novel approaches: A review article. Iranian journal of parasitology 2018 ,13 , 1-10. - 4.
Menendez, C. Malaria during pregnancy: a priority area of malaria research and control. Parasitology today 1995 ,11 , 178-183, doi:10.1016/0169-4758(95)80151-0. - 5.
Martinsen, E.S.; Perkins, S.L.; Schall, J.J. A three-genome phylogeny of malaria parasites (Plasmodium and closely related genera): evolution of life-history traits and host switches. Molecular phylogenetics and evolution 2008 ,47 , 261-273. - 6.
Gallup, J.L.; Sachs, J.D. The economic burden of malaria. The American journal of tropical medicine and hygiene 2001 ,64 , 85-96. - 7.
Malaria, W. Key Facts. Geneva. World Health Organization 2020 . - 8.
Guerra, C.A.; Howes, R.E.; Patil, A.P.; Gething, P.W.; Van Boeckel, T.P.; Temperley, W.H.; Kabaria, C.W.; Tatem, A.J.; Manh, B.H.; Elyazar, I.R. The international limits and population at risk of Plasmodium vivax transmission in 2009. PLoS Negl Trop Dis 2010 ,4 , e774. - 9.
Win, T.T.; Jalloh, A.; Tantular, I.S.; Tsuboi, T.; Ferreira, M.U.; Kimura, M.; Kawamoto, F. Molecular analysis of Plasmodium ovale variants. Emerging infectious diseases 2004 ,10 , 1235-1240. - 10.
Déchamps, S.; Maynadier, M.; Wein, S.; Gannoun-Zaki, L.; Maréchal, E.; Vial, H.J. Rodent and nonrodent malaria parasites differ in their phospholipid metabolic pathways. Journal of lipid research 2010 ,51 , 81-96. - 11.
Cox-Singh, J.; Davis, T.M.; Lee, K.-S.; Shamsul, S.S.; Matusop, A.; Ratnam, S.; Rahman, H.A.; Conway, D.J.; Singh, B. Plasmodium knowlesi malaria in humans is widely distributed and potentially life threatening. Clinical infectious diseases 2008 ,46 , 165-171. - 12.
Rosenberg, R.; Wirtz, R.A.; Schneider, I.; Burge, R. An estimation of the number of malaria sporozoites ejected by a feeding mosquito. Transactions of the Royal Society of Tropical Medicine and Hygiene 1990 ,84 , 209-212. - 13.
Cowman, A.F.; Healer, J.; Marapana, D.; Marsh, K. Malaria: biology and disease. Cell 2016 ,167 , 610-624. - 14.
Molina-Franky, J.; Cuy-Chaparro, L.; Camargo, A.; Reyes, C.; Gómez, M.; Salamanca, D.R.; Patarroyo, M.A.; Patarroyo, M.E. Plasmodium falciparum pre-erythrocytic stage vaccine development. Malaria journal 2020 ,19 , 56. - 15.
Tandel, N.; Tyagi, R.K. Chapter 5 Malaria. In Molecular Advancements in Tropical Diseases Drug Discovery , Misra Guari, V.S., Ed. 2020; 10.1016/b978-0-12-821202-8.00005-0pp. 95-116. - 16.
Monasch, R.; Reinisch, A.; Steketee, R.W.; Korenromp, E.L.; Alnwick, D.; Bergevin, Y. Child coverage with mosquito nets and malaria treatment from population-based surveys in African countries: a baseline for monitoring progress in roll back malaria. The American journal of tropical medicine and hygiene 2004 ,71 , 232-238. - 17.
Skwarczynski, M.; Chandrudu, S.; Rigau-Planella, B.; Islam, M.; Cheong, Y.S.; Liu, G.; Wang, X.; Toth, I.; Hussein, W.M. Progress in the Development of Subunit Vaccines against Malaria. Vaccines 2020 ,8 , 373. - 18.
Nájera, J.A.; González-Silva, M.; Alonso, P.L. Some lessons for the future from the Global Malaria Eradication Programme (1955-1969). PLoS Med 2011 ,8 , e1000412. - 19.
van den Berg, H. Global status of DDT and its alternatives for use in vector control to prevent disease. Environmental health perspectives 2009 ,117 , 1656-1663. - 20.
Mabaso, M.L.; Sharp, B.; Lengeler, C. Historical review of malarial control in southern African with emphasis on the use of indoor residual house-spraying. Tropical Medicine & International Health 2004 ,9 , 846-856. - 21.
Tren, R.; Bate, R. When politics kills: malaria and the DDT story ; Liberty Institute: 2000; Vol. 7. - 22.
Dhiman, S. Are malaria elimination efforts on right track? An analysis of gains achieved and challenges ahead. Infectious diseases of poverty 2019 ,8 , 1-19. - 23.
WHO. Malaria: fact sheet ; World Health Organization. Regional Office for the Eastern Mediterranean: 2019. - 24.
Hemingway, J.; Shretta, R.; Wells, T.N.; Bell, D.; Djimdé, A.A.; Achee, N.; Qi, G. Tools and strategies for malaria control and elimination: what do we need to achieve a grand convergence in malaria? PLoS biology 2016 ,14 , e1002380. - 25.
Elimination, m.R.C.P.o.T.f.M. malERA: An updated research agenda for diagnostics, drugs, vaccines, and vector control in malaria elimination and eradication. PLoS medicine 2017 ,14 , e1002455. - 26.
Kaehler, N.; Adhikari, B.; Cheah, P.Y.; Day, N.P.; Paris, D.H.; Tanner, M.; Pell, C. The promise, problems and pitfalls of mass drug administration for malaria elimination: a qualitative study with scientists and policymakers. International health 2019 ,11 , 166-176. - 27.
Wang, J.; Xu, C.; Wong, Y.K.; Li, Y.; Liao, F.; Jiang, T.; Tu, Y. Artemisinin, the magic drug discovered from traditional Chinese medicine. Engineering 2019 ,5 , 32-39. - 28.
Organization, W.H. Guidelines for the treatment of malaria ; World Health Organization: 2015. - 29.
Hetzel, M.W.; Genton, B. Mass drug administration for malaria elimination: do we understand the settings well enough? BMC medicine 2018 ,16 , 1-3. - 30.
Dahl, E.L.; Rosenthal, P.J. Multiple antibiotics exert delayed effects against the Plasmodium falciparum apicoplast. Antimicrobial agents and chemotherapy 2007 ,51 , 3485-3490. - 31.
Gaillard, T.; Madamet, M.; Tsombeng, F.F.; Dormoi, J.; Pradines, B. Antibiotics in malaria therapy: which antibiotics except tetracyclines and macrolides may be used against malaria? Malaria journal 2016 ,15 , 1-10. - 32.
Greenwood, B.; Targett, G. The mysteries of immunity to malaria. Lancet 2011 ,377 , 1729-1730. - 33.
Ramharter, M.; Winkler, H.; Kremsner, P.G.; Adegnika, A.A.; Willheim, M.; Winkler, S. Age-dependency of Plasmodium falciparum-specific and non-specific T cell cytokine responses in individuals from a malaria-endemic area. European cytokine network 2005 ,16 , 135-143. - 34.
Doolan, D.; Dobano, C.; Baird, J. Acquired immunity to malaria. 610 Clin Microbiol Rev 22: 13-36. Table of Contents 2009 ,611 . - 35.
Long, C.A.; Zavala, F. Immune responses in malaria. Cold Spring Harbor perspectives in medicine 2017 ,7 , a025577. - 36.
Nussenzweig, R.S.; Vanderberg, J.; Most, H.; Orton, C. Protective Immunity produced by the Injection of X-irradiated Sporozoites of Plasmodium berghei. Nature 1967 ,216 , 160-162, doi:10.1038/216160a0. - 37.
Clyde, D.F.; Most, H.; McCarthy, V.C.; Vanderberg, J.P. Immunization of man against sporozite-induced falciparum malaria. The American journal of the medical sciences 1973 ,266 , 169-177, doi:10.1097/00000441-197309000-00002. - 38.
Clyde, D.F. Immunization of man against falciparum and vivax malaria by use of attenuated sporozoites. Am J Trop Med Hyg 1975 ,24 , 397-401, doi:10.4269/ajtmh.1975.24.397. - 39.
Langhorne, J.; Ndungu, F.M.; Sponaas, A.-M.; Marsh, K. Immunity to malaria: more questions than answers. Nature immunology 2008 ,9 , 725-732. - 40.
Tran, T.M.; Li, S.; Doumbo, S.; Doumtabe, D.; Huang, C.-Y.; Dia, S.; Bathily, A.; Sangala, J.; Kone, Y.; Traore, A. An intensive longitudinal cohort study of Malian children and adults reveals no evidence of acquired immunity to Plasmodium falciparum infection. Clinical Infectious Diseases 2013 ,57 , 40-47. - 41.
Portugal, S.; Carret, C.; Recker, M.; Armitage, A.E.; Gonçalves, L.A.; Epiphanio, S.; Sullivan, D.; Roy, C.; Newbold, C.I.; Drakesmith, H. Host-mediated regulation of superinfection in malaria. Nature medicine 2011 ,17 , 732-737. - 42.
Marques-da-Silva, C.; Peissig, K.; Kurup, S.P. Pre-Erythrocytic Vaccines against Malaria. Vaccines 2020 ,8 , 400. - 43.
Rieckmann, K.; Beaudoin, R.L.; Cassells, J.; Sell, K. Use of attenuated sporozoites in the immunization of human volunteers against falciparum malaria. Bulletin of the World Health Organization 1979 ,57 , 261-265. - 44.
Rieckmann, K.H.; Carson, P.E.; Beaudoin, R.L.; Cassells, J.S.; Sell, K.W. Sporozoite induced immunity in man against an Ethiopian strain of Plasmodium falciparum. Transactions of the Royal Society of Tropical Medicine and Hygiene 1974 ,68 , 258-259. - 45.
Herrington, D.A.; Nardin, E.H.; Losonsky, G.; Bathurst, I.C.; Barr, P.J.; Hollingdale, M.R.; Edelman, R.; Levine, M.M. Safety and immunogenicity of a recombinant sporozoite malaria vaccine against Plasmodium vivax. The American journal of tropical medicine and hygiene 1991 ,45 , 695-701. - 46.
Egan, J.E.; Hoffman, S.L.; Haynes, J.D.; Sadoff, J.C.; Schneider, I.; Grau, G.E.; Hollingdale, M.R.; Ballou, W.R.; Gordon, D.M. Humoral immune responses in volunteers immunized with irradiated Plasmodium falciparum sporozoites. The American journal of tropical medicine and hygiene 1993 ,49 , 166-173. - 47.
Edelman, R.; Hoffman, S.L.; Davis, J.R.; Beier, M.; Sztein, M.B.; Losonsky, G.; Herrington, D.A.; Eddy, H.A.; Hollingdale, M.R.; Gordon, D.M. Long-term persistence of sterile immunity in a volunteer immunized with X-irradiated Plasmodium falciparum sporozoites. Journal of Infectious Diseases 1993 ,168 , 1066-1070. - 48.
Gwadz, R.; Cochrane, A.; Nussenzweig, V.; Nussenzweig, R. Preliminary studies on vaccination of rhesus monkeys with irradiated sporozoites of Plasmodium knowlesi and characterization of surface antigens of these parasites. Bulletin of the world Health Organization 1979 ,57 , 165-173. - 49.
Huff, C.G.; Marchbank, D.F.; Shiroishi, T. Changes in infectiousness of malarial gametocytes. II. Analysis of the possible causative factors. Experimental Parasitology 1958 ,7 , 399-417. - 50.
Mitchell, G.H.; Butcher, G.; Cohen, S. Merozoite vaccination against Plasmodium knowlesi malaria. Immunology 1975 ,29 , 397. - 51.
Cohen, S.; McGregor, I.; Carrington, S. Gamma-globulin and acquired immunity to human malaria. Nature 1961 ,192 , 733-737. - 52.
Bouharoun-Tayoun, H.; Attanath, P.; Sabchareon, A.; Chongsuphajaisiddhi, T.; Druilhe, P. Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes. The Journal of experimental medicine 1990 ,172 , 1633-1641. - 53.
Sabchareon, A.; Burnouf, T.; Ouattara, D.; Attanath, P.; Bouharoun-Tayoun, H.; Chantavanich, P.; Foucault, C.; Chongsuphajaisiddhi, T.; Druilhe, P. Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria. The American journal of tropical medicine and hygiene 1991 ,45 , 297-308. - 54.
Diggs, C.; CL, D.; BT, W.; RM, W. The protective effect of African human immunoglobulin G in Aotus trivirgatus infected with Asian Plasmodium falciparum. Proceedings of the Helminthological Society of Washington 1972 ,39 , 449-456. - 55.
Hill, A.V. Vaccines against malaria. Philosophical Transactions of the Royal Society B: Biological Sciences 2011 ,366 , 2806-2814. - 56.
Doolan, D.L.; Hoffman, S.L. Pre–erythrocytic–stage immune effector mechanisms in Plasmodium spp. infections. Philosophical Transactions of the Royal Society of London . Series B: Biological Sciences1997 ,352 , 1361-1367. - 57.
Zavala, F.; Tam, J.P.; Hollingdale, M.R.; Cochrane, A.H.; Quakyi, I.; Nussenzweig, R.S.; Nussenzweig, V. Rationale for development of a synthetic vaccine against Plasmodium falciparum malaria. Science 1985 ,228 , 1436-1440. - 58.
Good, M.F.; Maloy, W.L.; Lunde, M.N.; Margalit, H.; Cornette, J.L.; Smith, G.L.; Moss, B.; Miller, L.H.; Berzofsky, J.A. Construction of synthetic immunogen: use of new T-helper epitope on malaria circumsporozoite protein. Science 1987 ,235 , 1059-1062. - 59.
Collins, W.E.; Anders, R.F.; Pappaioanou, M.; Campbell, G.H.; Brown, G.V.; Kemp, D.J.; Coppel, R.L.; Skinner, J.C.; Andrysiak, P.M.; Favaloro, J.M. Immunization of Aotus monkeys with recombinant proteins of an erythrocyte surface antigen of Plasmodium falciparum. Nature 1986 ,323 , 259-262. - 60.
Patarroyo, M.E.; Amador, R.; Clavijo, P.; Moreno, A.; Guzman, F.; Romero, P.; Tascon, R.; Franco, A.; Murillo, L.A.; Ponton, G. A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria. Nature 1988 ,332 , 158-161. - 61.
Stoute, J.A.; Slaoui, M.; Heppner, D.G.; Momin, P.; Kester, K.E.; Desmons, P.; Wellde, B.T.; Garçon, N.; Krzych, U.; Marchand, M. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. New England Journal of Medicine 1997 ,336 , 86-91. - 62.
Bojang, K.A.; Milligan, P.J.; Pinder, M.; Vigneron, L.; Alloueche, A.; Kester, K.E.; Ballou, W.R.; Conway, D.J.; Reece, W.H.; Gothard, P. Efficacy of RTS, S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. The Lancet 2001 ,358 , 1927-1934. - 63.
Schofield, L.; Ferreira, A.; Altszuler, R.; Nussenzweig, V.; Nussenzweig, R. Interferon-gamma inhibits the intrahepatocytic development of malaria parasites in vitro. The Journal of Immunology 1987 ,139 , 2020-2025. - 64.
Hoffman, S.L.; Isenbarger, D.; Long, G.W.; Sedegah, M.; Szarfman, A.; Waters, L.; Hollingdale, M.R.; Van der Meide, P.H.; Finbloom, D.S.; Ballou, W.R. Sporozoite vaccine induces genetically restricted T cell elimination of malaria from hepatocytes. Science 1989 ,244 , 1078-1081. - 65.
Hoffman, S.L.; Weiss, W.; Mellouk, S.; Sedegah, M. Irradiated sporozoite vaccine induces cytotoxic T lymphocytes that recognize malaria antigens on the surface of infected hepatocytes. Immunology letters 1990 ,25 , 33-38. - 66.
Hoffman, S.; Isenbarger, D.; Long, G.; Sedegah, M.; Szarfman, A.; Mellouk, S.; Ballou, W. T lymphocytes from mice immunized with irradiated sporozoites eliminate malaria from hepatocytes. Bulletin of the World Health Organization 1990 ,68 , 132. - 67.
Rénia, L.; Grillot, D.; Marussig, M.; Corradin, G.; Miltgen, F.; Lambert, P.; Mazier, D.; Del Giudice, G. Effector functions of circumsporozoite peptide-primed CD4+ T cell clones against Plasmodium yoelii liver stages. The Journal of Immunology 1993 ,150 , 1471-1478. - 68.
Weiss, W.; Mellouk, S.; Houghten, R.A.; Sedegah, M.; Kumar, S.; Good, M.; Berzofsky, J.; Miller, L.; Hoffman, S. Cytotoxic T cells recognize a peptide from the circumsporozoite protein on malaria-infected hepatocytes. The Journal of experimental medicine 1990 ,171 , 763-773. - 69.
Wang, R.; Doolan, D.L.; Le, T.P.; Hedstrom, R.C.; Coonan, K.M.; Charoenvit, Y.; Jones, T.R.; Hobart, P.; Margalith, M.; Ng, J. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 1998 ,282 , 476-480. - 70.
McConkey, S.J.; Reece, W.H.; Moorthy, V.S.; Webster, D.; Dunachie, S.; Butcher, G.; Vuola, J.M.; Blanchard, T.J.; Gothard, P.; Watkins, K. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nature medicine 2003 ,9 , 729-735. - 71.
Collins, K.A.; Snaith, R.; Cottingham, M.G.; Gilbert, S.C.; Hill, A.V. Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine. Scientific reports 2017 ,7 , 46621. - 72.
Vannice, K.S.; Brown, G.V.; Akanmori, B.D.; Moorthy, V.S. MALVAC 2012 scientific forum: accelerating development of second-generation malaria vaccines. Springer: 2012. - 73.
Mo, A.X.; Augustine, A.D. NIAID meeting report: Improving malaria vaccine strategies through the application of immunological principles. Vaccine 2014 ,32 , 1132-1138. - 74.
Duffy, P.E.; Gorres, J.P. Malaria vaccines since 2000: progress, priorities, products. npj Vaccines 2020 ,5 , 1-9. - 75.
Draper, S.J.; Sack, B.K.; King, C.R.; Nielsen, C.M.; Rayner, J.C.; Higgins, M.K.; Long, C.A.; Seder, R.A. Malaria vaccines: recent advances and new horizons. Cell host & microbe 2018 ,24 , 43-56. - 76.
D’antonio, L.; Keshavarz-Valian, H.; Alger, N. Malaria vaccine antigen (s): detergent solubilization, partial isolation, and recovery of immunoprotective activity. Infection and immunity 1984 ,43 , 442-444. - 77.
Edozien, J.; Gilles, H.; Udeozo, I. Adult and cord-blood gamma-globulin and immunity to malaria in Nigerians. Lancet 1962 , 951-955. - 78.
Siddiqui, W.A. An effective immunization of experimental monkeys against a human malaria parasite, Plasmodium falciparum .Science 1977 ,197 , 388-389. - 79.
Sirima, S.B.; Cousens, S.; Druilhe, P. Protection against malaria by MSP3 candidate vaccine. New England Journal of Medicine 2011 ,365 , 1062-1064. - 80.
Spring, M.D.; Cummings, J.F.; Ockenhouse, C.F.; Dutta, S.; Reidler, R.; Angov, E.; Bergmann-Leitner, E.; Stewart, V.A.; Bittner, S.; Juompan, L. Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A. PloS one 2009 ,4 , e5254. - 81.
Payne, R.O.; Milne, K.H.; Elias, S.C.; Edwards, N.J.; Douglas, A.D.; Brown, R.E.; Silk, S.E.; Biswas, S.; Miura, K.; Roberts, R. Demonstration of the blood-stage Plasmodium falciparum controlled human malaria infection model to assess efficacy of theP. falciparum apical membrane antigen 1 vaccine, FMP2. 1/AS01. The Journal of infectious diseases2016 ,213 , 1743-1751. - 82.
Sirima, S.B.; Mordmüller, B.; Milligan, P.; Ngoa, U.A.; Kironde, F.; Atuguba, F.; Tiono, A.B.; Issifou, S.; Kaddumukasa, M.; Bangre, O. A phase 2b randomized, controlled trial of the efficacy of the GMZ2 malaria vaccine in African children. Vaccine 2016 ,34 , 4536-4542. - 83.
Barr, P.J.; Green, K.M.; Gibson, H.L.; Bathurst, I.C.; Quakyi, I.A.; Kaslow, D.C. Recombinant Pfs25 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in experimental animals. The Journal of experimental medicine 1991 ,174 , 1203-1208. - 84.
Menon, V.; Kapulu, M.C.; Taylor, I.; Jewell, K.; Li, Y.; Hill, F.; Long, C.A.; Miura, K.; Biswas, S. Assessment of antibodies induced by multivalent transmission-blocking malaria vaccines. Frontiers in immunology 2018 ,8 , 1998. - 85.
Kapulu, M.; Da, D.; Miura, K.; Li, Y.; Blagborough, A.; Churcher, T.; Nikolaeva, D.; Williams, A.R.; Goodman, A.; Sangare, I. Comparative assessment of transmission-blocking vaccine candidates against Plasmodium falciparum. Scientific reports 2015 ,5 , 11193. - 86.
Read, D.; Lensen, A.; Begarnie, S.; Haley, S.; Raza, A.; Carter, R. Transmission-blocking antibodies against multiple, non-variant target epitopes of the Plasmodium falciparum gamete surface antigen Pfs230 are all complement-fixing. Parasite immunology 1994 ,16 , 511-519. - 87.
Walsh, F. Malaria vaccine gets green light. BBC News Online 2015 . - 88.
RTS, S.C.T.P. Efficacy and safety of the RTS, S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS medicine 2014 ,11 , e1001685. - 89.
Bejon, P.; Lusingu, J.; Olotu, A.; Leach, A.; Lievens, M.; Vekemans, J.; Mshamu, S.; Lang, T.; Gould, J.; Dubois, M.-C. Efficacy of RTS, S/AS01E vaccine against malaria in children 5 to 17 months of age. New England Journal of Medicine 2008 ,359 , 2521-2532. - 90.
Moris, P.; Jongert, E.; van der Most, R.G. Characterization of T-cell immune responses in clinical trials of the candidate RTS, S malaria vaccine. Human vaccines & immunotherapeutics 2018 ,14 , 17-27. - 91.
Kester, K.E.; Cummings, J.F.; Ofori-Anyinam, O.; Ockenhouse, C.F.; Krzych, U.; Moris, P.; Schwenk, R.; Nielsen, R.A.; Debebe, Z.; Pinelis, E. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS, S/AS01B and RTS, S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. Journal of Infectious Diseases 2009 ,200 , 337-346. - 92.
Ockenhouse, C.F.; Regules, J.; Tosh, D.; Cowden, J.; Kathcart, A.; Cummings, J.; Paolino, K.; Moon, J.; Komisar, J.; Kamau, E. Ad35. CS. 01-RTS, S/AS01 heterologous prime boost vaccine efficacy against sporozoite challenge in healthy malaria-naive adults. PloS one 2015 ,10 , e0131571. - 93.
Garcon, N.; Van Mechelen, M. Recent clinical experience with vaccines using MPL-and QS-21-containing adjuvant systems. Expert review of vaccines 2011 ,10 , 471-486. - 94.
Polhemus, M.E.; Remich, S.A.; Ogutu, B.R.; Waitumbi, J.N.; Otieno, L.; Apollo, S.; Cummings, J.F.; Kester, K.E.; Ockenhouse, C.F.; Stewart, A. Evaluation of RTS, S/AS02A and RTS, S/AS01B in adults in a high malaria transmission area. PloS one 2009 ,4 , e6465. - 95.
Ansong, D.; Asante, K.P.; Vekemans, J.; Owusu, S.K.; Owusu, R.; Brobby, N.A.; Dosoo, D.; Osei-Akoto, A.; Osei-Kwakye, K.; Asafo-Adjei, E. T cell responses to the RTS, S/AS01 E and RTS, S/AS02 D malaria candidate vaccines administered according to different schedules to Ghanaian children. PLoS One 2011 ,6 , e18891. - 96.
Srikiatkhachorn, A. What translatable knowledge from dengue vaccine design can we pass onto future anti-parasitic vaccine development? Taylor & Francis: 2020. - 97.
Langowski, M.D.; Khan, F.A.; Bitzer, A.A.; Genito, C.J.; Schrader, A.J.; Martin, M.L.; Soto, K.; Zou, X.; Hadiwidjojo, S.; Beck, Z. Optimization of a Plasmodium falciparum circumsporozoite protein repeat vaccine using the tobacco mosaic virus platform. Proceedings of the National Academy of Sciences 2020 ,117 , 3114-3122. - 98.
Goh, Y.S.; McGuire, D.; Rénia, L. Vaccination with sporozoites: models and correlates of protection. Frontiers in immunology 2019 ,10 , 1227. - 99.
Coelho, C.H.; Doritchamou, J.Y.A.; Zaidi, I.; Duffy, P.E. Advances in malaria vaccine development: report from the 2017 malaria vaccine symposium. NPJ vaccines 2017 ,2 , 34-34, doi:10.1038/s41541-017-0035-3. - 100.
Belnoue, E.; Costa, F.T.; Frankenberg, T.; Vigário, A.M.; Voza, T.; Leroy, N.; Rodrigues, M.M.; Landau, I.; Snounou, G.; Rénia, L. Protective T cell immunity against malaria liver stage after vaccination with live sporozoites under chloroquine treatment. The Journal of Immunology 2004 ,172 , 2487-2495. - 101.
Roestenberg, M.; Teirlinck, A.C.; McCall, M.B.; Teelen, K.; Makamdop, K.N.; Wiersma, J.; Arens, T.; Beckers, P.; Van Gemert, G.; van de Vegte-Bolmer, M. Long-term protection against malaria after experimental sporozoite inoculation: an open-label follow-up study. The Lancet 2011 ,377 , 1770-1776. - 102.
Bijker, E.M.; Schats, R.; Obiero, J.M.; Behet, M.C.; van Gemert, G.-J.; van de Vegte-Bolmer, M.; Graumans, W.; van Lieshout, L.; Bastiaens, G.J.; Teelen, K. Sporozoite immunization of human volunteers under mefloquine prophylaxis is safe, immunogenic and protective: a double-blind randomized controlled clinical trial. PLoS One 2014 ,9 , e112910. - 103.
Mordmüller, B.; Surat, G.; Lagler, H.; Chakravarty, S.; Ishizuka, A.S.; Lalremruata, A.; Gmeiner, M.; Campo, J.J.; Esen, M.; Ruben, A.J. Sterile protection against human malaria by chemoattenuated PfSPZ vaccine. Nature 2017 ,542 , 445-449. - 104.
Patel, H.; Althubaiti, N.; Parmar, R.; Yadav, N.; Joshi, U.; Tyagi, R.K.; Krzych, U.; Dalai, S.K. Parasite load stemming from immunization route determines the duration of liver-stage immunity. Parasite immunology 2019 ,41 , e12622. - 105.
Epstein, J.; Tewari, K.; Lyke, K.; Sim, B.; Billingsley, P.; Laurens, M.; Gunasekera, A.; Chakravarty, S.; James, E.; Sedegah, M. Live attenuated malaria vaccine designed to protect through hepatic CD8+ T cell immunity. Science 2011 ,334 , 475-480. - 106.
Hoffman, S.L.; Goh, L.M.; Luke, T.C.; Schneider, I.; Le, T.P.; Doolan, D.L.; Sacci, J.; De la Vega, P.; Dowler, M.; Paul, C. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. The Journal of infectious diseases 2002 ,185 , 1155-1164. - 107.
Lyke, K.E.; Ishizuka, A.S.; Berry, A.A.; Chakravarty, S.; DeZure, A.; Enama, M.E.; James, E.R.; Billingsley, P.F.; Gunasekera, A.; Manoj, A. Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection. Proceedings of the National Academy of Sciences 2017 ,114 , 2711-2716. - 108.
Kaiser, K.; Matuschewski, K.; Camargo, N.; Ross, J.; Kappe, S.H. Differential transcriptome profiling identifies Plasmodium genes encoding pre-erythrocytic stage-specific proteins. Molecular microbiology 2004 ,51 , 1221-1232. - 109.
Jobe, O.; Donofrio, G.; Sun, G.; Liepinsh, D.; Schwenk, R.; Krzych, U. Immunization with radiation-attenuated Plasmodium berghei sporozoites induces liver cCD8α+ DC that activate CD8+ T cells against liver-stage malaria. PloS one 2009 ,4 , e5075. - 110.
Aly, A.S.; Mikolajczak, S.A.; Rivera, H.S.; Camargo, N.; Jacobs-Lorena, V.; Labaied, M.; Coppens, I.; Kappe, S.H. Targeted deletion of SAP1 abolishes the expression of infectivity factors necessary for successful malaria parasite liver infection. Molecular microbiology 2008 ,69 , 152-163. - 111.
Spring, M.; Murphy, J.; Nielsen, R.; Dowler, M.; Bennett, J.W.; Zarling, S.; Williams, J.; de la Vega, P.; Ware, L.; Komisar, J. First-in-human evaluation of genetically attenuated Plasmodium falciparum sporozoites administered by bite of Anopheles mosquitoes to adult volunteers. Vaccine 2013 ,31 , 4975-4983. - 112.
Kublin, J.G.; Mikolajczak, S.A.; Sack, B.K.; Fishbaugher, M.E.; Seilie, A.; Shelton, L.; VonGoedert, T.; Firat, M.; Magee, S.; Fritzen, E. Complete attenuation of genetically engineered Plasmodium falciparum sporozoites in human subjects. Science translational medicine 2017 ,9 . - 113.
Roestenberg, M.; Walk, J.; van der Boor, S.C.; Langenberg, M.C.; Hoogerwerf, M.-A.; Janse, J.J.; Manurung, M.; Yap, X.Z.; García, A.F.; Koopman, J.P.R. A double-blind, placebo-controlled phase 1/2a trial of the genetically attenuated malaria vaccine PfSPZ-GA1. Science Translational Medicine 2020 ,12 . - 114.
Nlinwe, O.N.; Kusi, K.A.; Adu, B.; Sedegah, M. T-cell responses against Malaria: Effect of parasite antigen diversity and relevance for vaccine development. Vaccine 2018 ,36 , 2237-2242. - 115.
Cockburn, I.A.; Chen, Y.-C.; Overstreet, M.G.; Lees, J.R.; Van Rooijen, N.; Farber, D.L.; Zavala, F. Prolonged antigen presentation is required for optimal CD8+ T cell responses against malaria liver stage parasites. PLoS Pathog 2010 ,6 , e1000877. - 116.
Parmar, R.; Patel, H.; Yadav, N.; Parikh, R.; Patel, K.; Mohankrishnan, A.; Bhurani, V.; Joshi, U.; Dalai, S.K. Infectious sporozoites of Plasmodium berghei effectively activate liver CD8α+ dendritic cells. Frontiers in immunology 2018 ,9 , 192. - 117.
Yamauchi, L.M.; Coppi, A.; Snounou, G.; Sinnis, P. Plasmodium sporozoites trickle out of the injection site. Cellular microbiology 2007 ,9 , 1215-1222. - 118.
Bongfen, S.E.; Torgler, R.; Romero, J.F.; Renia, L.; Corradin, G. Plasmodium berghei-infected primary hepatocytes process and present the circumsporozoite protein to specific CD8+ T cells in vitro. The Journal of Immunology 2007 ,178 , 7054-7063. - 119.
Tavares, J.; Formaglio, P.; Thiberge, S.; Mordelet, E.; Van Rooijen, N.; Medvinsky, A.; Ménard, R.; Amino, R. Role of host cell traversal by the malaria sporozoite during liver infection. Journal of experimental medicine 2013 ,210 , 905-915. - 120.
Ishizuka, A.S.; Lyke, K.E.; DeZure, A.; Berry, A.A.; Richie, T.L.; Mendoza, F.H.; Enama, M.E.; Gordon, I.J.; Chang, L.-J.; Sarwar, U.N. Protection against malaria at 1 year and immune correlates following PfSPZ vaccination. Nature medicine 2016 ,22 , 614-623. - 121.
Li, X.; Huang, J.; Zhang, M.; Funakoshi, R.; Sheetij, D.; Spaccapelo, R.; Crisanti, A.; Nussenzweig, V.; Nussenzweig, R.S.; Tsuji, M. Human CD8+ T cells mediate protective immunity induced by a human malaria vaccine in human immune system mice. Vaccine 2016 ,34 , 4501-4506. - 122.
Freeman, B.E.; Hammarlund, E.; Raué, H.-P.; Slifka, M.K. Regulation of innate CD8+ T-cell activation mediated by cytokines. Proceedings of the National Academy of Sciences 2012 ,109 , 9971-9976. - 123.
da Silva, H.B.; Fonseca, R.; dos Anjos Cassado, A.; de Salles, E.M.; de Menezes, M.N.; Langhorne, J.; Perez, K.R.; Cuccovia, I.M.; Ryffel, B.; Barreto, V.M. In vivo approaches reveal a key role for DCs in CD4+ T cell activation and parasite clearance during the acute phase of experimental blood-stage malaria. PLoS Pathog 2015 ,11 , e1004598. - 124.
Waterfall, M.; Black, A.; Riley, E. γδ+ T cells preferentially respond to live rather than killed malaria parasites. Infection and immunity 1998 ,66 , 2393-2398. - 125.
Pombo, D.J.; Lawrence, G.; Hirunpetcharat, C.; Rzepczyk, C.; Bryden, M.; Cloonan, N.; Anderson, K.; Mahakunkijcharoen, Y.; Martin, L.B.; Wilson, D. Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. The Lancet 2002 ,360 , 610-617. - 126.
GOODIER, M.R.; TARGETT, G.A. Polyclonal T-cell responses to Plasmodium falciparum gametocytes in malaria nonexposed donors. Parasite immunology 1997 ,19 , 419-425. - 127.
Abeles, S.R.; Chuquiyauri, R.; Tong, C.; Vinetz, J.M. Human host-derived cytokines associated with Plasmodium vivax transmission from acute malaria patients to Anopheles darlingi mosquitoes in the Peruvian Amazon. The American journal of tropical medicine and hygiene 2013 ,88 , 1130-1137. - 128.
Harte, P.; Rogers, N.; Targett, G. Role of T cells in preventing transmission of rodent malaria. Immunology 1985 ,56 , 1. - 129.
Kurup, S.P.; Butler, N.S.; Harty, J.T. T cell-mediated immunity to malaria. Nature Reviews Immunology 2019 ,19 , 457-471. - 130.
von der Weid, T.; Kopf, M.; Köhler, G.; Langhorne, J. The immune response to Plasmodium chabaudi malaria in interleukin-4-deficient mice. European journal of immunology 1994 ,24 , 2285-2293. - 131.
Kumaratilake, L.; Ferrante, A. IL-4 inhibits macrophage-mediated killing of Plasmodium falciparum in vitro. A possible parasite-immune evasion mechanism. The Journal of Immunology 1992 ,149 , 194-199. - 132.
James, K.R.; Soon, M.S.; Sebina, I.; Fernandez-Ruiz, D.; Davey, G.; Liligeto, U.N.; Nair, A.S.; Fogg, L.G.; Edwards, C.L.; Best, S.E. IFN regulatory factor 3 balances Th1 and T follicular helper immunity during nonlethal blood-stage Plasmodium infection. The Journal of Immunology 2018 ,200 , 1443-1456. - 133.
Mastelic, B.; Freitas do Rosario, A.P.; Veldhoen, M.; Renauld, J.-C.; Jarra, W.; Sponaas, A.-M.; Roetynck, S.; Stockinger, B.; Langhorne, J. IL-22 protects against liver pathology and lethality of an experimental blood-stage malaria infection. Frontiers in immunology 2012 ,3 , 85. - 134.
Kimura, D.; Miyakoda, M.; Kimura, K.; Honma, K.; Hara, H.; Yoshida, H.; Yui, K. Interleukin-27-producing CD4+ T cells regulate protective immunity during malaria parasite infection. Immunity 2016 ,44 , 672-682. - 135.
D’Ombrain, M.C.; Robinson, L.J.; Stanisic, D.I.; Taraika, J.; Bernard, N.; Michon, P.; Mueller, I.; Schofield, L. Association of early interferon-γ production with immunity to clinical malaria: a longitudinal study among Papua New Guinean children. Clinical Infectious Diseases 2008 ,47 , 1380-1387. - 136.
Inoue, S.I.; Niikura, M.; Asahi, H.; Kawakami, Y.; Kobayashi, F. γδ T cells modulate humoral immunity against Plasmodium berghei infection. Immunology 2018 ,155 , 519-532. - 137.
Gilbert, S.C.; Plebanski, M.; Harris, S.J.; Allsopp, C.E.; Thomas, R.; Layton, G.T.; Hill, A.V. A protein particle vaccine containing multiple malaria epitopes. Nature biotechnology 1997 ,15 , 1280-1284. - 138.
Neafsey, D.E.; Juraska, M.; Bedford, T.; Benkeser, D.; Valim, C.; Griggs, A.; Lievens, M.; Abdulla, S.; Adjei, S.; Agbenyega, T. Genetic diversity and protective efficacy of the RTS, S/AS01 malaria vaccine. New England Journal of Medicine 2015 ,373 , 2025-2037. - 139.
Sedegah, M.; Peters, B.; Hollingdale, M.R.; Ganeshan, H.D.; Huang, J.; Farooq, F.; Belmonte, M.N.; Belmonte, A.D.; Limbach, K.J.; Diggs, C. Vaccine strain-specificity of protective HLA-restricted class 1 P. falciparum epitopes. PLoS One2016 ,11 , e0163026. - 140.
Guttinger, M.; Caspers, P.; Takacs, B.; Trzeciak, A.; Gillessen, D.; Pink, J.; Sinigaglia, F. Human T cells recognize polymorphic and non-polymorphic regions of the Plasmodium falciparum circumsporozoite protein. The EMBO journal 1988 ,7 , 2555-2558. - 141.
Ewer, K.J.; Sierra-Davidson, K.; Salman, A.M.; Illingworth, J.J.; Draper, S.J.; Biswas, S.; Hill, A.V. Progress with viral vectored malaria vaccines: A multi-stage approach involving “unnatural immunity”. Vaccine 2015 ,33 , 7444-7451. - 142.
Li, Y.; Leneghan, D.B.; Miura, K.; Nikolaeva, D.; Brian, I.J.; Dicks, M.D.; Fyfe, A.J.; Zakutansky, S.E.; De Cassan, S.; Long, C.A. Enhancing immunogenicity and transmission-blocking activity of malaria vaccines by fusing Pfs25 to IMX313 multimerization technology. Scientific reports 2016 ,6 , 18848. - 143.
Skwarczynski, M.; Toth, I. Peptide-based synthetic vaccines. Chemical science 2016 ,7 , 842-854. - 144.
Perdomo-Celis, F.; Taborda, N.A.; Rugeles, M.T. CD8+ T-cell response to HIV infection in the era of antiretroviral therapy. Frontiers in immunology 2019 ,10 , 1896. - 145.
Osii, R.S.; Otto, T.D.; Garside, P.; Ndungu, F.M.; Brewer, J.M. The Impact of Malaria Parasites on Dendritic Cell–T Cell Interaction. Frontiers in Immunology 2020 ,11 , 1597. - 146.
King, T.; Lamb, T. Interferon-γ: the Jekyll and Hyde of malaria. PLoS Pathog 2015 ,11 , e1005118.